Dr Pavlos Msaouel speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the combination of sitravatinib and nivolumab for the treatment of advanced clear cell renal cell cancer (aCCRCC) in patients who have progressed on prior VEGF-targeted therapy.

He explains the background of this early phase I/II study, along with the main results achieved in this study.

Dr Msaouel concludes that this combination did to demonstrate any unexpected safety signals and achieved higher objective responses and longer disease control compared to the use of nivolumab alone.